AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griggs, D. J.
Right arrow Articles by Piddock, L. J. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griggs, D. J.
Right arrow Articles by Piddock, L. J. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 699-707, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.699-707.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Incidence and Mechanism of Ciprofloxacin Resistance in Campylobacter spp. Isolated from Commercial Poultry Flocks in the United Kingdom before, during, and after Fluoroquinolone Treatment

Deborah J. Griggs,1 Maggie M. Johnson,1 Jennifer A. Frost,2 Tom Humphrey,3 Frieda Jørgensen,4 and Laura J. V. Piddock1*

Antimicrobial Agents Research Group, Division of Immunity & Infection, University of Birmingham Medical School, Birmingham,1 Campylobacter Reference Unit, Health Protection Agency Specialist & Reference Microbiology Division, Colindale, London,2 School of Clinical Veterinary Science,3 Food Microbiology Collaborating Unit, Health Protection Agency South West, School of Clinical Veterinary Science, University of Bristol, Langford, Bristol, United Kingdom4

Received 20 January 2004/ Returned for modification 11 June 2004/ Accepted 26 September 2004

Five commercial broiler flocks were treated with a fluoroquinolone for a clinically relevant infection. Fresh feces from individual chickens and environmental samples were cultured for campylobacters before, during, and weekly posttreatment until slaughter. Both Campylobacter jejuni and C. coli were isolated during all treatment phases. An increased proportion of quinolone-resistant strains was seen during treatment, and these strains persisted posttreatment. One quinolone-resistant isolate of each species, each serotype, and each phage type from each sample at all treatment phases was examined for its phenotype and mechanism of resistance. Two resistant phenotypes were isolated: Nalr Cipr and Nalr Cips. The majority (269 of 290) of fluoroquinolone-resistant isolates, whether they were C. jejuni or C. coli, had a mutation in gyrA that resulted in the substitution Thr-86->Ile. The other gyrA mutations detected were Thr-86->Ala (n = 17) and Asp-90->Asn (n = 10). The genotypic variation, based on the silent mutations in gyrA identified by the denaturing high-performance liquid chromatography pattern and DNA sequencing, was used to supplement typing data and provided evidence for both the spread of preexisting resistant strains and the selection of spontaneous resistant mutants in treated flocks. Multidrug resistance was significantly (P < 0.01) associated with resistance to ciprofloxacin. Twenty-five percent (73 of 290) of ciprofloxacin-resistant isolates but only 13% (24 of 179) of susceptible isolates were resistant to three or more unrelated antimicrobial agents. In conclusion, quinolone-resistant campylobacters were isolated from commercial chicken flocks in high numbers following therapy with a veterinary fluoroquinolone. Most ciprofloxacin-resistant isolates had the GyrA substitution Thr-86->Ile. Resistant isolates were isolated from the feces of some flocks up to the point of slaughter, which may have consequences for public health.


* Corresponding author. Mailing address: Antimicrobial Agents Research Group, Division of Immunity & Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom. Phone: 0121 414 6966. Fax: 0121 414 3454. E-mail: l.j.v.piddock{at}bham.ac.uk.


Antimicrobial Agents and Chemotherapy, February 2005, p. 699-707, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.699-707.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.